AXL and malignant colon neoplasm: In the present study, we found that a low level expression of ANO1 in the aggressive TAZ-AXL-CTGF-high subgroup of colon cancer patients is associated with prolonged survival (high level to low level of ANO1 expression; mean survival from 59 to 100 months and from 66 to 107 month in GSE14333 and GSE17538 patient datasets, respectively), suggesting that pharmacological inhibition of ANO1 may represent a novel therapeutic approach for this group of patients with aggressive colon cancer.